Compare CCB & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCB | DCTH |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 633.6M | 578.4M |
| IPO Year | 2018 | 2015 |
| Metric | CCB | DCTH |
|---|---|---|
| Price | $43.26 | $14.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $51.00 | $24.00 |
| AVG Volume (30 Days) | 198.0K | ★ 264.6K |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | $4.17 | $24.61 |
| Revenue Next Year | $20.89 | $24.27 |
| P/E Ratio | ★ N/A | $364.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.56 | $8.12 |
| 52 Week High | $120.05 | $17.42 |
| Indicator | CCB | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 37.69 |
| Support Level | $36.09 | $11.43 |
| Resistance Level | $50.78 | $16.51 |
| Average True Range (ATR) | 1.90 | 0.53 |
| MACD | 0.39 | -0.01 |
| Stochastic Oscillator | 32.15 | 8.06 |
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.